Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q92963: Variant p.Ser35Thr

GTP-binding protein Rit1
Gene: RIT1
Feedback?
Variant information Variant position: help 35 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Serine (S) to Threonine (T) at position 35 (S35T, p.Ser35Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Found in patients with features of Noonan syndrome; likely pathogenic. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 35 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 219 The length of the canonical sequence.
Location on the sequence: help PAGLSREYKLVMLGAGGVGK S AMTMQFISHRFPEDHDPTIE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 219 GTP-binding protein Rit1
Binding site 28 – 35
Alternative sequence 1 – 36 Missing. In isoform 2.
Mutagenesis 35 – 35 S -> N. Dominant negative. Loss of interaction with AFDN, RLF and RALGDS.
Mutagenesis 53 – 53 T -> S. Loss of interaction with AFDN, RLF and RALGDS; when associated with L-79.
Mutagenesis 55 – 55 E -> G. Loss of interaction with AFDN, but not with RLF and RALGDS; when associated with L-79.
Helix 34 – 43



Literature citations
Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
Aoki Y.; Niihori T.; Banjo T.; Okamoto N.; Mizuno S.; Kurosawa K.; Ogata T.; Takada F.; Yano M.; Ando T.; Hoshika T.; Barnett C.; Ohashi H.; Kawame H.; Hasegawa T.; Okutani T.; Nagashima T.; Hasegawa S.; Funayama R.; Nagashima T.; Nakayama K.; Inoue S.; Watanabe Y.; Ogura T.; Matsubara Y.;
Am. J. Hum. Genet. 93:173-180(2013)
Cited for: FUNCTION; INVOLVEMENT IN NS8; VARIANTS NS8 GLY-57; GLY-81; LEU-82; ILE-90 AND ALA-95; CHARACTERIZATION OF VARIANTS NS8 GLY-57; GLY-81; LEU-82; ILE-90 AND ALA-95; VARIANTS THR-35; VAL-82; PRO-83 AND HIS-89;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.